[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse KIRREL2

Summary
SymbolKIRREL2
Namekin of IRRE like 2 (Drosophila)
Aliases NLG1; NEPH3; FILTRIN; DKFZp564A1164; MGC15718; kin of irregular chiasm-like protein 2; nephrin-like gene 1; ......
Chromosomal Location19q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Single-pass type I membrane protein Note=Localized along the sites of the cell contacts. Colocalizes with E-Cadherin and beta-catenin.
Domain PF08205 CD80-like C2-set immunoglobulin domain
PF07679 Immunoglobulin I-set domain
Function

May regulate basal insulin secretion.

> Gene Ontology
 
Biological Process GO:0001933 negative regulation of protein phosphorylation
GO:0042326 negative regulation of phosphorylation
Molecular Function -
Cellular Component GO:0036056 filtration diaphragm
GO:0036057 slit diaphragm
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-1500931: Cell-Cell communication
R-HSA-373753: Nephrin interactions
Summary
SymbolKIRREL2
Namekin of IRRE like 2 (Drosophila)
Aliases NLG1; NEPH3; FILTRIN; DKFZp564A1164; MGC15718; kin of irregular chiasm-like protein 2; nephrin-like gene 1; ......
Chromosomal Location19q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between KIRREL2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolKIRREL2
Namekin of IRRE like 2 (Drosophila)
Aliases NLG1; NEPH3; FILTRIN; DKFZp564A1164; MGC15718; kin of irregular chiasm-like protein 2; nephrin-like gene 1; ......
Chromosomal Location19q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of KIRREL2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolKIRREL2
Namekin of IRRE like 2 (Drosophila)
Aliases NLG1; NEPH3; FILTRIN; DKFZp564A1164; MGC15718; kin of irregular chiasm-like protein 2; nephrin-like gene 1; ......
Chromosomal Location19q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of KIRREL2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.6970.116
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.7010.352
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.6980.266
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.0110.984
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.5750.584
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.7550.556
729033130MelanomaallAnti-PD-1 (nivolumab) 26232.0420.003
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.5970.242
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11122.6240.083
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 4800.999
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.1470.843
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1630.491
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of KIRREL2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103033.3-33.30.231
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.45.51.90.66
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.46.80.61
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.85.9-1.11
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 382710.5010.50.135
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221313.6013.60.279
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolKIRREL2
Namekin of IRRE like 2 (Drosophila)
Aliases NLG1; NEPH3; FILTRIN; DKFZp564A1164; MGC15718; kin of irregular chiasm-like protein 2; nephrin-like gene 1; ......
Chromosomal Location19q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of KIRREL2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolKIRREL2
Namekin of IRRE like 2 (Drosophila)
Aliases NLG1; NEPH3; FILTRIN; DKFZp564A1164; MGC15718; kin of irregular chiasm-like protein 2; nephrin-like gene 1; ......
Chromosomal Location19q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of KIRREL2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by KIRREL2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolKIRREL2
Namekin of IRRE like 2 (Drosophila)
Aliases NLG1; NEPH3; FILTRIN; DKFZp564A1164; MGC15718; kin of irregular chiasm-like protein 2; nephrin-like gene 1; ......
Chromosomal Location19q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of KIRREL2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolKIRREL2
Namekin of IRRE like 2 (Drosophila)
Aliases NLG1; NEPH3; FILTRIN; DKFZp564A1164; MGC15718; kin of irregular chiasm-like protein 2; nephrin-like gene 1; ......
Chromosomal Location19q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of KIRREL2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolKIRREL2
Namekin of IRRE like 2 (Drosophila)
Aliases NLG1; NEPH3; FILTRIN; DKFZp564A1164; MGC15718; kin of irregular chiasm-like protein 2; nephrin-like gene 1; ......
Chromosomal Location19q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between KIRREL2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolKIRREL2
Namekin of IRRE like 2 (Drosophila)
Aliases NLG1; NEPH3; FILTRIN; DKFZp564A1164; MGC15718; kin of irregular chiasm-like protein 2; nephrin-like gene 1; ......
Chromosomal Location19q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting KIRREL2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.